NSE
Astec LifeSciences LimitedASTEC
Astec LifeSciences Limited is an Indian pharmaceutical company involved in the manufacturing of APIs (Active Pharmaceutical Ingredients) and formulations.
| Key products | APIs, Formulations |
|---|---|
| Geography | India |
| Competitors | Dr Reddy's Laboratories, Cipla |
AI-generated overview — verify before relying on it.
Net institutional flow
+₹0.4 Cr
Institutional buyers
3 in / 3 out
High-impact filings
0 · tilt Neutral
Next corporate action
—
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | ATALREAL | +₹4.8 Cr | 91 | — | — | — | — |
| 2 | ASTECThis | +₹0 Cr | 2 | — | — | — | — |
| 3 | MOBIKWIK | +₹0 Cr | 12 | — | — | — | — |
| 4 | QUADFUTURE | +₹0 Cr | 34 | — | — | — | — |
| 5 | IRMENERGY | — | — | — | — | — | — |
| 6 | MTNL | — | — | — | — | — | — |
| 7 | GATECH | — | — | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
SWOT
Strengths
- • Diversified portfolio with a strong presence in API manufacturing
- • Established relationships with major pharmaceutical companies
- • State-of-the-art manufacturing facilities
- • Strong research and development capabilities
Weaknesses
- • Dependence on a few key customers
- • High operating costs due to regulatory compliance
- • Competition from low-cost producers in emerging markets
- • Limited presence in the US market
Opportunities
- • Growing demand for generic APIs in emerging markets
- • Increasing focus on sustainable and eco-friendly manufacturing practices
- • Expansion into new product categories such as biosimilars
- • Partnerships with pharmaceutical companies to develop new products
Threats
- • Intensifying competition from generic drug manufacturers
- • Regulatory changes and compliance risks
- • Fluctuations in raw material prices and supply chain disruptions
- • Economic downturn affecting consumer spending on healthcare
AI-generated from our data — verify before relying on it.
- 2026-05-18BulkBUY · ₹9.3 CrNK SECURITIES RESEARCH PRIVATE LIMITED
- 2026-05-18BulkSELL · ₹9.3 CrNK SECURITIES RESEARCH PRIVATE LIMITED
- 2026-05-18NetDay net −₹0 Cr
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
No scored filings for ASTEC yet.
2 deals · 2026-05-18 → 2026-05-18
| Date | Counterparty | Type | Side | Value |
|---|---|---|---|---|
| 2026-05-18 | NK SECURITIES RESEARCH PRIVATE LIMITED | Prop / churn | BUY | ₹9.3 Cr |
| 2026-05-18 | NK SECURITIES RESEARCH PRIVATE LIMITED | Prop / churn | SELL | ₹9.3 Cr |
2 deals in the selected window — corporate actions are scoped to the same period. ~2 years of history available.
News & chatter on ASTEC
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.